- Research article
- Open Access
- Open Peer Review
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population
© Cai et al.; licensee BioMed Central. 2015
- Received: 14 October 2014
- Accepted: 5 February 2015
- Published: 26 February 2015
Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays complex and adverse roles on atherosclerosis. Current study was to investigate whether increased plasma Lp-PLA2 level is independently associated with the severity of coronary artery diseases (CAD).
Totally 781 participants were enrolled and performed coronary angiography (CAG) to figure out the number of coronary artery stenosis. According to clinical presentation, electrocardiography, cardiac biomarker, and CAG result, participants were divided into control (excluded CAD), stable angina (SA), unstable angina (UA) and acute myocardial infarction (AMI) groups. Baseline characteristics were recorded. Statistical analyses were performed to evaluate the relationship between Lp-PLA2 level and CAD severity.
Plasma levels of Lp-PLA2 in control, SA, UA and AMI groups were 7.38(3.33-9.26) μg/L, 5.94(2.89-8.55) μg/L, 8.56(5.34-11.95) μg/L and 8.68(5.56-13.27) μg/L respectively (P < 0.001). After adjusted for age, gender, smoking, diabetes mellitus, hypertension, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), apoprotein A (apoA) and statins, Lp-PLA2 level was still independently associated with CAD severity, with odd ratio (OR) of 1.055 (AMI group versus control group, 95% confidence interval (CI) 1.021-1.090, P < 0.05). Additionally, the relationship between Lp-PLA2 level and the number of stenosis coronary artery was also assessed. Lp-PLA2 levels in control, single-vessel, and multiple-vessels stenosis groups were 7.38(3.33-9.26) μg/L, 7.80 (4.05-10.76) μg/L and 8.29(5.18-11.76) μg/L respectively (P for trend < 0.001). After adjusted for age, gender, smoking, diabetes mellitus, hypertension, LDL-C and HDL-C, apoA and statins, Lp-PLA2 level remained independently associated with the number of coronary artery stenosis, with OR of 1.053 (multiple-vessels stenosis group versus control group, 95% CI 1.025-1.069, P < 0.05).
Increased Lp-PLA2 level is independently associated with CAD severity, and Lp-PLA2 level may be used to discriminate those who are at increased risk of cardiovascular events.
- Coronary artery disease
- Lipoprotein-associated phospholipase A2
Atherosclerotic cardiovascular disease (ASCVD) is still the leading cause of morbidity and mortality worldwide despite great advances on diagnosis and treatment have been achieved in the past decades . Knowingly, inflammation plays critical and continuous roles on the initiation and progression of atherosclerosis and ASCVD [2,3], and increased serum level of inflammatory biomarker such as high sensitivity C-reactive protein (Hs-CRP) has been recognized as an important predictor for cardiovascular diseases risk [4,5].
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme excreting predominantly from atherosclerotic plaques by macrophages and neutrophils and then circulating in blood stream . Previously, clinical epidemiological studies showed that increased plasma level of Lp-PLA2 was associated with increased risk of cardiovascular events such as myocardial infarction and ischemic stroke [7-9], and Lp-PLA2 inhibitors could significantly reduce the incident of cardiovascular events as compared to placebo treatment [10,11]. Data from basic experiments further supported clinical findings [12-14]. For example, in animal model of hyperlipidemia and hyperglycemia, as compared to placebo treatment, Lp-PLA2 inhibitor reduced macrophage accumulation, diminished necrotic lipid-core volume and thickened fibrous cap of coronary atherosclerotic plaque . Therefore, Lp-PLA2 has been incorporated into cardiovascular diseases risk assessment algorithm . Nevertheless, despite striking and encouraging findings from previous studies, two recent large randomized, controlled and prospective clinical trials showed that darapladib treatment, a selective Lp-PLA2 antagonist, resulted in no better improvement of clinical outcomes in patients with stable or unstable coronary artery diseases (CAD) [16,17].
In light of the conflicting findings of previous studies, we conducted a cross-sectional and observational clinical study to investigate whether increased plasma level of Lp-PLA2 is independently associated with the severity of CAD, and we believe that the clinical implication of our study would add, if any, valuable information to address whether Lp-PLA2 could be used to predict CAD risk in the future.
Studied subjects and protocols
Studied subjects were enrolled from January of 2013 to April of 2014 after informed consent was obtained, and our current study was approved by the Ethical Committee of Guangdong General Hospital. Coronary angiography was performed to figure out the number of coronary artery stenosis in terms of single or multiple vessels stenosis (≥50% stenosis). Those without significant coronary artery stenosis (<50% stenosis) were defined as control group. Clinical presentations in terms of stable angina (SA), unstable angina (UA) or acute myocardial infarction (AMI) were diagnosed according to clinical manifestation, electrocardiography findings and cardiac biomarkers by two experts of cardiology. Demographic characteristics including age, gender, family history of ASCVD, smoking status, hypertension and diabetes mellitus were recorded by questionnaire and were double-checked by two experts of cardiology. Fasting venous blood at admission was drawn for the assessment of fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), apoprotein A (apoA), apoprotein B (apoB), lipoprotein (a) (Lp(a)) and glycated hemoglobin (HbA1c). Plasma level of Lp-PLA2 at admission was evaluated by enzyme-linking immune-absorbent assay (ELISA, commercially brought from Shanghai Yueyan Biological.
Technology Co.,Ltd , and the inter-assay variant is less than 11% and intra-assay variant is less than 9%) and the assay range was 1 μg/L to 20 μg/L. All performances were conducted in accordance to manufacture’s instruction and three independent experiments were performed in duplicate. For the purpose of figuring out whether increased plasma level of Lp-PLA2 was associated with the severity of CAD, all participants were divided into different subgroups on the basis of two major categories in terms of the severity of clinical presentation (stable angina, unstable angina, or acute myocardial infarction) and the number of stenosis coronary artery (single or multiple vessels stenosis).
The primary endpoint of our current study was to evaluate the correlation between plasma level of Lp-PLA2 and the severity of CAD, including the severity of clinical presentation and the number of coronary artery stenosis.
Continuous data was presented as mean ± SD or median (inter-quartile range) appropriately, and compared by the Student’s t-test when data was normally distributed, otherwise compared by the Wilcoxon rank-sum test. Categorical data was presented as percentage and compared by χ2 test. Univariate and multivariate regression analyses were performed to evaluate the relationship between Lp-PLA2 value and the severity of CAD. Statistical analyses were performed by using SPSS software version 18.0 (SPSS, Inc., Chicago, Illinois). A value of P < 0.05 was considered significant.
Baseline characteristics of studied subjects
Baseline characteristics of participants
60.57 ± 9.57
62.77 ± 10.68
64.70 ± 10.83
61.79 ± 11.84
Family history (%)
Diabetes mellitus (%)
6.33 ± 1.59
6.50 ± 1.37
6.44 ± 1.25
6.48 ± 1.38
4.54 ± 1.07
4.29 ± 1.01
4.41 ± 1.22
4.43 ± 1.08
1.74 ± 1.40
1.59 ± 0.97
1.60 ± 0.95
1.64 ± 1.13
2.72 ± 0.89
2.57 ± 0.86
2.67 ± 0.98
2.79 ± 0.91
1.08 ± 0.26
1.02 ± 0.27
1.00 ± 0.25
0.90 ± 0.17
1.18 ± 0.24
1.14 ± 0.32
1.10 ± 0.25
0.98 ± 0.20
0.81 ± 0.18
0.77 ± 0.19
0.80 ± 0.22
0.85 ± 0.28
Relationship between Lp-PLA2 level and severity of clinical presentation
Participants were divided into 4 groups in accordance to the severity of clinical presentation. Plasma level of Lp-PLA2 in the control (n = 103), SA (n = 190), UA (n = 293) and AMI (n = 195) groups were 7.38(3.33-9.26) μg/L, 5.94(2.89-8.55) μg/L, 8.56(5.34-11.95) μg/L and 8.68(5.56-13.27) μg/L respectively (AMI group versus control group, P < 0.001). After adjusted for age, gender, smoking, diabetes mellitus, hypertension, Lp(a), LDL-C, HDL-C, apoA and statins, Lp-PLA2 level was still independently associated with severity of CAD, with odd ratio (OR) of 1.055 (AMI versus control group, 95% confidence interval (CI) 1.021-1.090, P < 0.05).
Relationship between Lp-PLA2 level and the number of coronary artery stenosis
In light of angiography findings, participants were divided into control, single, or multiple vessels stenosis groups. Lp-PLA2 levels in the control (n = 103), single-vessel stenosis (n = 193), and multiple-vessels stenosis (n = 485) groups were 7.38(3.33-9.26) μg/L, 7.80(4.05-10.76) μg/L, and 8.29(5.18-11.76) μg/L respectively (P for trend < 0.001). After adjusted for age, gender, smoking, diabetes mellitus, hypertension, Lp(a), LDL-C, HDL-C, apoA and statins, Lp-PLA2 level remained independently associated with the number of coronary artery stenosis, with OR of 1.053 (multiple-vessels stenosis group versus control group, 95% CI 1.025-1.069, P < 0.05).
Owing to its unique effects on the initiation and progression of atherosclerosis [18,19], Lp-PLA2 has been recognized as a novel and promising biomarker for cardiovascular diseases risk evaluation, and data from clinical and basic research also showed that Lp-PLA2 decrease was beneficial for retarding atherosclerosis progression and reducing cardiovascular events [10,20]. Nevertheless, results from two recent clinical trials named STABILITY and SOLID-TIMI52 did not show cardiovascular benefits of darapladib therapy in patients with stable or unstable CAD [16,17]. Consistent with previous epidemiological studies, findings from our current study shows that in the real world population increased plasma level of Lp-PLA2 is not only independently associated with more vessels stenosis but also portends a higher risk of cardiovascular events such as acute coronary syndrome.
Lp-PLA2 is an enzyme predominantly excreted from atherosclerotic plaques by inflammatory cells and circulates in blood stream. Pathologically, Lp-PLA2 augments inflammation and oxidation by means of degrading oxidized-LDL into two potent pro-atherosclerotic and pro-thrombotic intermediates named lysophosphotidylcholine (Lyso-PC) and oxidized non-esterified fatty acids (oxNEFAs), which subsequently results in endothelium dysfunction, foam cells formation, necrotic lipid-core expansion and fibrous cap thinning . Therefore, it is reasonable to speculate that increased plasma level of Lp-PLA2 may contribute coronary artery stenosis progression and accelerate atherosclerotic plaque rupture. Data from current cross-sectional study also supported this hypothesis. As compared to those without significant coronary artery stenosis (control group), plasma level of Lp-PLA2 was gradually and significantly increased in single and multiple vessels stenosis groups. Previously, data from Shahar Lavi and colleagues also showed that early coronary atherosclerosis in humans was characterized by Lp-PLA2 production, and local coronary production of Lyso-PC, the active product of Lp-PLA2, was associated with endothelial dysfunction and atherogenesis . Therefore, it might be possible that the higher Lp-PLA2 level the more severe of endothelial dysfunction and atherosclerosis would be. Although our current study has not tested the differences of endothelial function in each group, accumulating evidence from basic and clinical research might be compelling to demonstrate the positive relationship between increased Lp-PLA2 level and the impairment of endothelial function. Apart from endothelium-associated mechanisms, Lyso-PC and oxNEFAs also play important and complex roles on atherosclerotic plaques development . Pathologically, both Lyso-PC and oxNEFAs are capable of up-regulating intra-cellular adhesion molecules (ICAM) expression, enhancing inflammatory cells infiltration and accumulation, promoting foam cells formation and expanding necrotic lipid-core . Overall, Lp-PLA2 per se and its product concomitantly initiate and accelerate atherosclerotic plaque development.
Of note, serum level of Lp(a) was significantly higher in the AMI group than that of the control group, while HDL-C and apoA were profoundly lower, suggesting that these dyslipidemia might be also associated with the CAD severity. However, after adjustment for these lipid profiles, Lp-PLA2 level remained independently associated with CAD severity. With regard to the anti-inflammation, anti-oxidation and endothelium-protective effects, one might speculate that statins might be capable to ameliorate the adverse effects resulted from Lp-PLA2 elevation. Nonetheless, data from previous studies showed the conflicting outcomes of statins therapy on Lp-PLA2 elevation. Present research showed no confounding effects of statins therapy on the relationship between Lp-PLA2 level and CAD severity.
On the second critical point, results from our study supported the notion that increased plasma level of Lp-PLA2 predicted a more unstable phenotype of coronary artery plaques. Of note, plasma levels of Lp-PLA2 were comparable in the control and stable angina groups (7.38(3.33-9.26) μg/L and 5.94(2.89-8.55) μg/L, respectively). Nonetheless, Lp-PLA2 levels were significantly elevated in the unstable angina and acute myocardial infarction groups (8.56(5.34-11.95) μg/L and 8.68(5.56-13.27) μg/L, respectively). This finding was consistent with previous reports [14,25]. Data from Frank D. Kolodgie et al. showed that Lp-PLA2 staining was more intense in human prone-rupture coronary atheroma than that with relatively stable plaque . Histologic and pathological results from basic research further supported clinical findings. The landmark research used hypercholesterolemic and diabetic swine showed that Lp-PLA2 played continuous role on coronary atherosclerotic plaque development . Darapladib treatment resulted in a considerable decrease in necrotic core area and reduced medial destruction, thereby resulting in relatively stable phenotype of plaques, which indirectly suggested that Lp-PLA2 promoting plaque instability. Of note that plasma levels of Lp-PLA2 were significantly higher in the UA and AMI groups than that of the control and SA groups. To our best knowledge, it might be due to Lp-PLA continuously releasing from unstable prone-rupture or ruptured plaque. Therefore, we considered that increasing Lp-PLA2 level might portend an upcoming cardiovascular event such as acute coronary syndrome.
There were limitations of our current study. First of all, unavoidable bias of cross-sectional study exists with regard to evaluate the relationship between Lp-PLA2 level and severity of CAD. Nonetheless, traditional risk factors had already been extensively adjusted and previous abundant evidence also supported the positive relationship between increased Lp-PLA2 level and cardiovascular diseases risks. Secondly, the ELISA kit used in our current study maybe not consistent with previous use and the assay range was quite different from previous studies. Therefore it should be cautious to interpret our findings since the reference value of plasma level of Lp-PLA in our study was not consistent with previous studies. Nevertheless, three independent experiments were performed in duplicate, therefore we believed that the significant difference of Lp-PLA2 level among each subgroup was convincing. Last but not the least, previous studies had shown the relationship between Lp-PLA2 level and CAD severity and it appeared that our study provided not much new information. However, with respect to the conflicting results about Lp-PLA2 antagonist on cardiovascular outcomes, we considered that data from our study might add more evidence regarding the adverse effects of Lp-PLA2 on ASCVD, future studies selecting appropriate subjects was still deserved to conduct.
Results from our study once again show that in patients with CAD, increased plasma level of Lp-PLA2 predicts an unstable phenotype of coronary atherosclerotic plaque and is also associated with more coronary artery stenosis. Dynamic evaluation of Lp-PLA2 level may provide prognostic value on cardiovascular diseases risk assessment.
This work was supported by the grants from the Technology Project Foundation of Guangdong Province, China (2009A030301004, 2011B031800021, 2011B061300034 and 2011B031800263), Guangdong Natural Science Foundation (S2012010009532), Guangdong Medical Research Foundation (B2011002), Cardiovascular medication grant of Guangdong Province (2011X25 and 2013X29), Medical Scientific Research Grant of the Health Ministry of Guangdong province, China (B2011310 and A2012663), and NSFC (81470571).
- Goff Jr DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino Sr RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73.View ArticlePubMedGoogle Scholar
- Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–26.View ArticlePubMedGoogle Scholar
- Libby P. Act local, act global: inflammation and the multiplicity of “vulnerable” coronary plaques. J Am Coll Cardiol. 2005;45(10):1600–2.View ArticlePubMedGoogle Scholar
- Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27(8):1788–95.View ArticlePubMedGoogle Scholar
- Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43.View ArticlePubMedGoogle Scholar
- Macphee CH, Nelson J, Zalewski A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol. 2006;6(2):154–61.View ArticlePubMedGoogle Scholar
- Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol. 2008;51(9):913–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. downloaded. Arterioscler Thromb Vasc Biol. 2006;26(11):2517–22.View ArticlePubMedGoogle Scholar
- Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109(7):837–42.View ArticlePubMedGoogle Scholar
- Mohler 3rd ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008;51(17):1632–41.View ArticlePubMedGoogle Scholar
- Berger JS, Ballantyne CM, Davidson MH, Johnson JL, Tarka EA, Lawrence D, et al. Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011;161(5):972–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118(11):1172–82.View ArticlePubMedGoogle Scholar
- Hu MM, Zhang J, Wang WY, Wu WY, Ma YL, Chen WH, et al. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin. 2011;32(10):1253–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Wilensky RL, Shi Y, Mohler 3rd ER, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14(10):1059–66.View ArticlePubMedPubMed CentralGoogle Scholar
- Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101(12A):51F–7.View ArticlePubMedGoogle Scholar
- White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–11.View ArticlePubMedGoogle Scholar
- O’Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312(10):1006–15.View ArticlePubMedGoogle Scholar
- Cai A, Zheng D, Qiu R, Mai W, Zhou Y. Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers. 2013;34(5):323–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol. 2009;20(5):415–20.View ArticlePubMedGoogle Scholar
- Daida H, Iwase T, Yagi S, Ando H, Nakajima H. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe. Circ J. 2013;77(6):1518–25.View ArticlePubMedGoogle Scholar
- Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2006;26(1):106–11.View ArticlePubMedGoogle Scholar
- Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007;115(21):2715–21.View ArticlePubMedGoogle Scholar
- Iwase M, Sonoki K, Sasaki N, Ohdo S, Higuchi S, Hattori H, et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis. 2008;196(2):931–6.View ArticlePubMedGoogle Scholar
- Papathanasiou AI, Lourida ES, Tsironis LD, Goudevenos JA, Tselepis AD. Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment. Atherosclerosis. 2008;196(1):289–97.View ArticlePubMedGoogle Scholar
- Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2523–9.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.